Literature DB >> 11824655

Visual evoked potentials in patients with psoriasis vulgaris.

A Grzybowski1, G Grzybowski, A Druzdz, R Zaba.   

Abstract

PURPOSE: The aim of this study is an estimation of the visual evoked potentials (VEP) in patients with psoriasis vulgaris. The role of the nervous system was pointed out in the pathogenesis of psoriasis. Also epidemiologic research confirms that patients with psoriasis are at increased risk of MS development.
MATERIALS AND METHODS: A group of 30 psoriatic males aged between 18 and 54 was examined. The results were compared with those obtained from a group of 30 healthy age-matched males and they were correlated with the psoriasis area and severity index (PASI), the skin surface area involved, duration of the disease and duration of the last relapse. In neurological and ophthalmological examinations no pathological symptoms were detected in either group. The VEP examination was executed using pattern reversal (pr) and pattern flash (pf) stimulation.
RESULTS: Using pf stimulation, in the group of patients with psoriasis vulgaris, a statistically significant elongation in the latency of P-100 and reduction of response amplitude, not related to the PASI, nor the skin surface area involved, nor duration of the last relapse, were observed.
CONCLUSIONS: The results of the study indicate subclinical damage of the visual pathway in patients with psoriasis vulgaris.

Entities:  

Mesh:

Year:  2001        PMID: 11824655     DOI: 10.1023/a:1013059807998

Source DB:  PubMed          Journal:  Doc Ophthalmol        ISSN: 0012-4486            Impact factor:   2.379


  17 in total

1.  A quantitative immunohistochemical study of the expression of integrins by nerves in psoriatic and normal skin.

Authors:  S M Andrew; B D Edwards; R J Chalmers; J B O'Driscoll
Journal:  Br J Dermatol       Date:  1992-10       Impact factor: 9.302

2.  [The ultrastructural changes in the nerve fibers of the skin in psoriasis].

Authors:  Z M Getling; V I Al'banova; V N Mordovtsev
Journal:  Vestn Dermatol Venerol       Date:  1990

3.  Increased plasma norepinephrine in psoriasis.

Authors:  G Ionescu; R Kiehl
Journal:  Acta Derm Venereol       Date:  1991       Impact factor: 4.437

Review 4.  Skin, immunity and the nervous system.

Authors:  L Misery
Journal:  Br J Dermatol       Date:  1997-12       Impact factor: 9.302

5.  [Electroencephalographic studies in psoriasis].

Authors:  Ch Kh Liu; Ch P Tsoĭ; B D Dé; G G Timoshin
Journal:  Vestn Dermatol Venerol       Date:  1990

6.  Intraepidermal nerve fiber expression of calcitonin gene-related peptide, vasoactive intestinal peptide and substance P in psoriasis.

Authors:  J Chan; B R Smoller; S P Raychauduri; W Y Jiang; E M Farber
Journal:  Arch Dermatol Res       Date:  1997-10       Impact factor: 3.017

7.  Eosinophils, pruritus and psoriasis: effects of treatment with etretinate or cyclosporin-A.

Authors:  R E Schopf; T Hultsch; J Lotz; M Bräutigam
Journal:  J Eur Acad Dermatol Venereol       Date:  1998-11       Impact factor: 6.166

8.  Psoriasis and polyneuropathy. Three case histories.

Authors:  S H Sindrup; H H Ibsen; J H Sindrup; E H Sindrup
Journal:  Acta Derm Venereol       Date:  1990       Impact factor: 4.437

9.  [Multiple sclerosis and psoriasis].

Authors:  W Cendrowski
Journal:  Wiad Lek       Date:  1989-05-01

10.  Neuropeptides and general neuronal marker in psoriasis--an immunohistochemical study.

Authors:  M S Al'Abadie; H J Senior; S S Bleehen; D J Gawkrodger
Journal:  Clin Exp Dermatol       Date:  1995-09       Impact factor: 3.470

View more
  2 in total

1.  Pattern VEP alterations in psoriatic patients may indicate a sub clinic optic neuritis.

Authors:  M Perossini; E Turio; T Perossini; M Romagnoli; S Benedetti; G Cei; P Barachini; M Nardi
Journal:  Doc Ophthalmol       Date:  2005 Mar-May       Impact factor: 2.379

2.  Relationship between retinal sensitivity and disease activity in patients with psoriasis vulgaris.

Authors:  Helin Deniz Demir; Göknur Kalkan; Semiha Kurt; Alper Güneş; Engin Sezer; Ünal Erkorkmaz
Journal:  Clinics (Sao Paulo)       Date:  2015-01       Impact factor: 2.365

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.